Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD)
- 9 January 2008
- journal article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 24 (2) , 515-535
Abstract
Conclusions of the recent NICE technology appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD) differ from recommendations by other Health Technology Assessment (HTA) agencies, such as the Scottish Medicines Consortium (CMS) and the Australian Pharmaceutical Benefits Advisory Committee (PBAC). NICE did not identify differences on grounds of clinical effectiveness between treatment options studied and issued technology guidance based on clinical profiles of compounds and on drug acquisition costs. The aim of the present study was to explore the robustness of NICE assessment methods when addressing a complex clinical problem such as the evaluation of ADHD treatment strategies. This robustness will be of interest to international policy-makers, given the widespread perception of NICE as a role model for the implementation of HTAs including economic evaluation. A qualitative case study was performed to critically appraise the technology assessment report (AR) underlying NICE conclusions, including a systematic search for and analysis of relevant literature. The AR produced on behalf of NICE was found to exhibit a range of anomalies. Search criteria were not applied consistently, and the available clinical evidence was not used optimally; selection of clinical endpoints and clinical trials for analysis were idiosyncratic. The primary cost-effectiveness model relied on six short-term studies only, and secondary extensions combined heterogeneous study designs and different clinical endpoints. Neither the distinction between efficacy and effectiveness nor the role of treatment compliance in ADHD was addressed adequately. Long-term extensions of the model were impaired by use of inappropriate discount rates and absence of consideration of long-term sequelae associated with ADHD. A review of the literature strongly suggests that the NICE assessment of ADHD treatment strategies was incomplete and likely prone to bias. It is concluded that NICE did not adequately accommodate a complex clinical decision problem. Although the present qualitative case study of one assessment cannot, and was not designed to, invalidate the NICE approach to economic evaluation of healthcare programs, this observation may have potentially far-reaching implications for the generalizability of NICE-like approaches.Keywords
This publication has 95 references indexed in Scilit:
- Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youthJournal of Psychopharmacology, 2006
- Predictors of antisocial behaviour in children with attention deficit hyperactivity disorderEuropean Child & Adolescent Psychiatry, 2006
- A review of the economic burden of ADHDCost Effectiveness and Resource Allocation, 2005
- Attention-Deficit/Hyperactivity Disorder Among Adolescents: A Review of the Diagnosis, Treatment, and Clinical ImplicationsPediatrics, 2005
- A Clinical Perspective of Attention-Deficit/Hyperactivity Disorder Into AdulthoodThe Journal of Clinical Psychiatry, 2004
- Driving impairments in teens and adults with attention-deficit/hyperactivity disorderPsychiatric Clinics of North America, 2004
- Attention-Deficit/Hyperactivity Disorder: Increased Costs for Patients and Their FamiliesJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- Children with attention deficit hyperactivity disorder and attendance at hospitalEuropean Journal of Emergency Medicine, 2003
- Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare SystemsPharmacoEconomics, 2003
- Attention Deficit Disorder and hospitalization due to injury among older adolescents in New South Wales, AustraliaJournal of Attention Disorders, 2002